Life Sciences

  Mwandama Mutanuka, a colleague of mine who’s involved in business process management (BPM) projects at Perficient, recently authored a blog post about how enterprise mobility can improve clinical research. He started his piece with news that highlighted Eli Lilly’s purchase of 15,000 iPads for employees, starting a few years back. Now, they’re upgrading to […]

  In a time when the turnover rate for clinical monitoring positions in the U.S. hovers around 25%, it’s more important than ever to do more with less. With risk-based monitoring (RBM), contract research organizations (CROs) and sponsors can leverage data in existing IT systems to spot, rectify, and prevent issues related to the execution […]

  Real-world data, the data generated about drugs and devices in real-world settings (e.g., routing doctor visits, hospital stays, etc.), can help develop more accurate product profiles. This is because the data comes from products that are no longer confined to the smaller, homogenous populations involved in clinical trials. More comprehensive profiles can help better […]

  Oracle’s third quarter 2016 earnings call was peppered with strong revenues and big wins in various categories. But what was most striking was the incredible progress the enterprise software powerhouse has made with regard to the cloud. Between CEO Safra Catz, CEO Mark Hurd (yes, they’re both CEOs), and Executive Chairman of the Board […]

  In my tenure here at Perficient, I’ve contributed to a number of guides for the life sciences industry. Each one has been informative and useful, but I can’t remember ever being as excited about any of them as I am about the newest one: Life Sciences is Going Digital. 

  Perficient’s Life Sciences practice regularly monitors the software release notes for several Oracle Health Sciences applications, as well as our own clinical and safety systems. The systems covered in our review are: 

  Now that April is here, I thought it would be neat to look back at what our readers found most interesting last month. Below are the top five blog posts Perficient’s life sciences practice wrote in March – they’re ranked in order of popularity, with number one being the most viewed piece. 

  At the end of 2015, Austin Frakt, a health economist, researcher, and contributor to The New York Times’ The Upshot, wrote about the life sciences industry’s lack of interest in developing medicines that prevent cancer. 

  On January 8, 2016, the FDA issued a warning letter that caught my attention. I can’t remember why I initially opened it; maybe because the company’s name had “pharm” in it, as opposed to “seafood” (which seems to be there a lot!). Once inside the letter, I found this in the opening paragraph: “This […]

  On January 14, 2016, Perficient hosted a webinar titled Leveraging Siebel CTMS for Risk-Based Monitoring. We received some good questions during the webinar and figured we’d share them (and the answers) with you. 

Medication non-adherence continues to be a big issue in the pharma industry, affecting clinical outcomes for both approved and investigational drugs. Sponsors, research organizations, and payers are looking to verify that what they’re studying or paying for is actually being used as directed. Various technologies, such as Proteus and AiCure, are being examined for these […]

  As we mentioned in our life sciences trends guide for 2016, patient recruitment is a constant challenge that needs to be confronted head-on with innovative tactics and technology. The mere fact that only 5% of cancer patients ever enroll in a trial is simply unacceptable, considering how connected we are in the digital era.